Clinical trials: Maintenance Therapy
Schizophrenia
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
- Trial name
- NCT01760889
- Testing
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg)
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Shire
Eosinophilic Gastroenteritis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.
- Trial name
- NCT05214768
- Testing
- CC-93538
- Where
- 25 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Celgene
Chronic Renal Failure, Chronic Kidney Disease
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)
The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- NCT00453973
- Testing
- peginesatide
- Where
- 20 sites in Bulgaria, Poland and 2 more
- Volunteers
- 114 people
- Sponsor
- Affymax
Ulcerative Colitis
A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, double-blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission compared with placebo in the treatment of participants with…
- Trial name
- HICKORY (NCT02100696)
- Testing
- Etrozulimab
- Where
- 184 sites in United States, Argentina and 22 more
- Volunteers
- 609 people
- Sponsor
- Hoffmann-La Roche
Insomnia
Implementing and Evaluating Computer-Based Interventions for Mental Health: Testing an Implementation Strategy for VA Outpatient Care
Internet-based self-help programs are personalized, self-guided interventions delivered over a computer, mobile device, or other Internet platform and focused on improving knowledge, awareness, or behavior change for a mental or…
- Trial name
- NCT03151083
- Testing
- Internet-based Self-help Insomnia Intervention
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Insomnia
Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia
Insomnia is a disorder in which people have inadequate or poor-quality sleep due to a number of factors, such as difficulty falling asleep, waking up frequently during the night with difficulty returning to sleep, waking up too…
- Trial name
- NCT05233761
- Testing
- Defined CBD
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Defined Research
Metastatic Endometrial Cancer
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.
- Trial name
- NCT03617679
- Testing
- Rucaparib
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of Colorado, Denver
Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
The goal of this clinical trial is to determine the toxicity and also the efficacy of a treatment that includes the following treatment: Two medications, bortezomib and dexamethasone (or BD), followed by autologous stem cell…
- Conditions
- Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
- Trial name
- NCT01383759
- Testing
- Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well capecitabine and celecoxib with or without radiation therapy works in treating patients with colorectal cancer that is newly diagnosed or has been previously treated with fluorouracil, and has…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- ADAPT (NCT01729923)
- Testing
- Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Multiple Myeloma
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT)…
- Trial name
- NCT05032820
- Testing
- Lenalidomide, bb2121, Cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin
Bipolar Mania, Bipolar Disorder
Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8…
- Trial name
- NCT00280566
- Testing
- Ziprasidone Oral Capsule
- Where
- 107 sites in United States, Chile and 11 more
- Volunteers
- 584 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hepatitis C, Chronic, Hepatitis C
A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
The main purpose of this pilot study is to investigate the safety, effectiveness and tolerability of the study medication in the treatment of people with chronic hepatitis C virus infection who regularly attend a…
- Conditions
- Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
- Trial name
- NCT03235154
- Testing
- sofosbuvir/velpatasvir
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Community Research Initiative of New England
Atrial Fibrillation
Prediction and Maintenance of Sinus Rhythm Among Atrial Fibrillation Patients
Atrial fibrillation (AF) is the most common heart rhythm disorder seen in clinical practice, with an estimated 2.7-6.1 million people in the U.S. affected by the disorder [1].
- Trial name
- NCT04313296
- Testing
- Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Crystal Blake-Parlin
Primary Insomnia
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
This is a randomised, placebo controlled study to evaluate the efficacy of a 3 week treatment period with Circadin® 2 mg in shortening sleep latency in patients with primary insomnia aged 18-80 with melatonin deficiency.
- Trial name
- NCT00397189
- Testing
- Circadin
- Where
- United Kingdom
- Volunteers
- 930 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Kidney Transplantation
Optima: Optimizing Prograf Therapy in Maintenance Allografts II
This study is designed to optimize calcineurin immunosuppressive regimens and evaluate immunological and non-immunological markers that may explain mechanistic differences in these agents and their effects.
- Trial name
- OPTIMAII (NCT00905515)
- Testing
- cyclosporine, Prograf (Tacrolimus)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- East Carolina University
Asthma
Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices
This study is conducted to assess the ease of device mastery of a placebo SYMBICORT TURBOHALER vs a placebo Budesonide/Formoterol SPIROMAX device among healthcare professionals in-training (HCP).
- Trial name
- HCP-ELIOT (NCT02570425)
- Testing
- Training on BF Spiromax followed by SYMBICORT Turbohaler, Training on SYMBICORT Turbohaler followed by BF Spiromax
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Research in Real-Life Ltd
Renal Disease, Sleep Disorders
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Sleep-wake dysregulation is a disturbance in the roughly 24-hour cycle of the circadian rhythm. Well known disorders presenting a sleep-wake dysregulation are seasonal affective disorder, jet lag and shift work.
- Trial name
- SleepTx-1 (NCT01256983)
- Testing
- Bright Light Therapy, Wait-list intervention
- Volunteers
- 30 people
- Sponsor
- University of Basel
Insomnia, Sleep Deprivation
Study of the Effects of HIRREM-SOP for Insomnia
Prior research studies have shown benefit for use of a technique called High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM®), to reduce symptoms of moderate to severe insomnia.
- Trial name
- NCT03607994
- Testing
- HIRREM-SOP, NCC
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Insomnia, Posttraumatic Stress Disorder
Suvorexant and Trauma Related Insomnia
Problems sleeping are common after exposure to highly threatening experiences and can occur with and without a diagnosis of posttraumatic stress disorder (PTSD).
- Trial name
- NCT02704754
- Testing
- suvorexant
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Howard University
Obesity
Financial vs. Non-Financial Rewards for Weight Loss and Weight Maintenance
Three of every four Veterans are overweight or obese, and weight loss is associated with reduced morbidity and mortality. The VA MOVE! program for weight loss is moderately effective but only reaches a small percentage of…
- Trial name
- NCT02957539
- Testing
- Financial rewards, Non-Financial rewards
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.